{
    "title": "115_hr4724",
    "content": "The Act titled \"Medicare IVIG Access Enhancement Act\" allows for a Medicare Patient IVIG Access Demonstration Project. The Secretary of Health and Human Services will establish a demonstration project under Medicare to evaluate the benefits of providing payment for in-home administration of intravenous immune globulin for chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. The project will last for 3 years and enroll up to 3,000 Medicare beneficiaries diagnosed with these conditions. The demonstration project allows Medicare beneficiaries with chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy to participate voluntarily and receive coverage under part B of Medicare. Payment for intravenous immune globulin will follow the payment methodology under section 1847A of the Social Security Act. Other items and services will be covered as well. The Secretary will establish a per-visit payment amount for in-home infusion of intravenous immune globulin for chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy, based on the national low-utilization payment amount for home health services. The payment amount shall not be less than the payment amount applied under the prospective payment system for home health services. The Secretary may waive requirements of title XVIII of the Social Security Act to carry out the demonstration project for in-home administration of intravenous immune globulin for primary immune deficiency diseases. A report evaluating the project's impact must be submitted to Congress within 3 years of enactment. An evaluation of the impact of the demonstration project on access for Medicare beneficiaries with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy to items and services needed for in-home administration of intravenous immune globin, along with an analysis of expanding or extending the project or implementing a new payment methodology for intravenous immune globulins in all care settings under part B of title XVIII of the Social Security Act. Recommendations for any expansion or extension deemed appropriate will be provided. The Secretary will submit a final report to Congress one year after the completion of the demonstration project, including an evaluation of the impact and recommendations for expansion or extension. Definitions include \"demonstration project\" as the project under this Act and \"Medicare beneficiary\" as an individual enrolled for benefits under part B of title XVIII of the Social Security Act."
}